S‐100B as an extra selection tool for FDG PET/CT scanning in follow‐up of AJCC stage III melanoma patients
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.25682
Abstract: This current study assessed the value of S‐100B measurement to guide fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scanning for detecting recurrent disease in stage III melanoma patients. read more here.
Keywords: iii melanoma; melanoma patients; stage iii; pet scanning ... See more keywords
Utility of PET/CT in patients with stage I–III melanoma
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-019-02252-2
Abstract: Purpose To study the utility of positron emission tomography with computerized tomography (PET/CT) in patients with a stage I–III melanoma. Patients and methods PET/CT findings from all patients with a stage I–III melanoma attended at… read more here.
Keywords: pet; stage iii; utility; iii melanoma ... See more keywords
Advances in the Management of Melanoma
Sign Up to like & getrecommendations! Published in 2017 at "Current Dermatology Reports"
DOI: 10.1007/s13671-017-0202-9
Abstract: Purpose of ReviewStage IV melanoma is an aggressive malignancy with the median survival historically being less than 1 year. Approximately 50% of melanomas contain an activating mutation in a targetable component of the mitogen-activated protein kinase… read more here.
Keywords: melanoma; management melanoma; stage iii; advances management ... See more keywords
Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma.
Sign Up to like & getrecommendations! Published in 2019 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000593
Abstract: Ipilimumab is approved for adjuvant melanoma treatment at a dose of 10 mg/kg, but its use is limited owing to high toxicity and treatment-associated costs. We retrospectively analyzed 29 patients who underwent complete resection of stage… read more here.
Keywords: adjuvant setting; treatment; ipilimumab; melanoma ... See more keywords
Adjuvant nodal field radiation in resected Stage III melanoma: A single‐centre retrospective study in Christchurch, New Zealand
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Imaging and Radiation Oncology"
DOI: 10.1111/1754-9485.13438
Abstract: Stage III melanoma is associated with poor outcomes. We studied the characteristics and outcomes of patients with resected Stage III melanoma before the routine use of adjuvant immunotherapy. Some of these patients received adjuvant nodal… read more here.
Keywords: resected stage; iii melanoma; radiation; stage iii ... See more keywords
Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-18-2847
Abstract: Purpose: Biomarkers are needed to stratify patients with stage II–III melanoma for clinical trials of adjuvant therapy because, while immunotherapy is protective, it also confers the risk of severe toxicity. We previously defined and validated… read more here.
Keywords: immune gene; stage iii; mip; melanoma ... See more keywords
Abstract CT121: Neoadjuvant combination targeted and immunotherapy for high-risk resectable stage III melanoma (NeoACTIVATE), NCT03554083
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2019-ct121
Abstract: Background: Standard treatment for stage III melanoma is surgery followed by consideration of adjuvant therapy. This strategy is inadequate for high-risk stage III patients who have a substantial risk of subsequent relapse and distant metastasis.… read more here.
Keywords: melanoma; high risk; stage iii; iii melanoma ... See more keywords
Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.2512
Abstract: 2512 Background: Since 2015, ipilimumab (Ipi) is an approved treatment for stage III melanoma based on a significantly (P=0.0013) prolonged recurrence-free survival (RFS) (Eggermont et al, Lancet Oncology, 2015). At a median follow-up of 5.3… read more here.
Keywords: stage iii; long term; stage; oncology ... See more keywords
Use of immunotherapy for stage-III and IV melanoma and likelihood of regional and distant lymph node resection and surgical resection for distant metastasis.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.9558
Abstract: 9558 Background: Immunotherapy (IMT) for stages-III and IV melanoma has dramatically changed overall prognosis and treatment strategies. The aim of this study was to evaluate if use of IMT significantly changed the likelihood of regional/distant… read more here.
Keywords: stage iii; regional distant; resection; melanoma ... See more keywords
Surgeon Assessment of the Technical Impact of Neoadjuvant Systemic Therapy on Operable Stage III Melanoma
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Surgical Oncology"
DOI: 10.1245/s10434-021-11112-9
Abstract: The effect of neoadjuvant systemic therapies (NST) on technical aspects of operation for resectable stage III melanoma is unknown. Prospective capture of the estimated and actual degree of difficulty of therapeutic lymphadenectomy at presentation and… read more here.
Keywords: iii melanoma; operable stage; stage iii; neoadjuvant systemic ... See more keywords
PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2021-1286
Abstract: Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-L1 inhibitor, has been shown to prolong survival in patients with advanced… read more here.
Keywords: recurrence; stage iii; iii; iii melanoma ... See more keywords